SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Man reaching the top and having success, throwing cash in air. Being successful in finance concept. Vector illustration
Infectious disease
Gilead Eyes HIV Market Domination With Twice-Yearly Yeztugo as GSK Trails
Analysts believe that Gilead’s new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.
July 2, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Business
TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects
Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean many companies are unlikely to ever recoup their investments.
June 25, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Judge hiiting tiny man by gavel. Bankruptcy, lawsuit, protest concept. Vector illustration.
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Pictured: Eli Lilly's biotechnology center in California
Obesity
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
Eli Lilly joins up with Camurus to make long-acting versions of the pharma’s obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of dosing.
June 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Rare diseases
FDA’s Prasad Vows To Make Rare Disease Drugs Available at ‘First Sign of Promise’
The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines to patients before they clear the traditional efficacy bar for authorization, Prasad said Tuesday.
June 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Robotic claw clutching a money stock illustration
Cell therapy
Gilead Gears Up To Challenge J&J in $20B Multiple Myeloma CAR -T Market
J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at least as good efficacy.
June 4, 2025
 · 
5 min read
 · 
Nick Paul Taylor
IV infusion set on yellow background, flat lay
Lung cancer
Roche and Jazz Link Drug Combo to Improved Survival in Phase III Lung Cancer Trial
Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could offer an alternative to monotherapy treatments from Roche and AstraZeneca.
June 3, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Abstract handshake
Mergers & acquisitions
Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio
Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.”
June 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor
concept - kidney tumor.
Cancer
Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg
Updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug secured approval for a type of kidney cancer in 2023.
June 2, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Facade of Moderna's building in Massachusetts
Vaccines
Moderna Wins FDA Approval for Next-Gen COVID-19 Vaccine Despite ‘Investor Nervousness’
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors worried.
June 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Medically accurate illustration of lung cancer. showing presence of cancerous tumor inside the lungs. 3d illustration
Lung Cancer
Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic
Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient populations.
May 30, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Workplace conflict Job rivalry, jealousy among colleagues concept, angry coworker fighting by pulling golden crown metaphor of job promotion position.
Cancer
Summit’s Campaign To Conquer Keytruda Nears First Global Phase III Data
Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other branded drugmakers are also seeking to improve on the blockbuster checkpoint inhibitor.
May 7, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Engraving human heart illustration set isolated on black background with CMYK color
Cardiovascular disease
Pfizer Mounts Defense of Cardiac Blockbuster as Alnylam, BridgeBio Enter Market
Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
April 22, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Doubtful businessman stands in front of a crossroad with road split in three different ways as arrows shows opposed courses. Business challenge, choosing a correct pathway. Difficult decision concept
Lung cancer
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
Even before the FDA’s recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate could hit $5.9 billion in 2030. However, the asset faced a series of setbacks in 2024.
January 21, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Photo of a GLP-1 injector pen on a blue background
glp-1
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
The data suggest the high dose nearly closes the efficacy gap with Zepbound.
January 17, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Load More